Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Weaver, Eric A ^a   Nehete, Pramod N ^c   Buchl, Stephanie S ^c   Senac, Julien S ^d   Palmer, Donna ^d   Ng, Philip ^d   Sastry, K Jagannadha ^c   Barry, Michael A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; FIRST GENERATION ADENOVIRUS VACCINE; GREEN FLUORESCENT PROTEIN; HELPER DEPENDENT ADENOVIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LUCIFERASE; REPLICATION COMPETENT ADENOVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; HELPER VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; LIVER INJURY; MACACA; MOUSE; NONHUMAN; SEROTYPE; TISSUE INJURY; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; COMPARATIVE STUDY; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS; IMMUNITY; IMMUNOLOGY; T LYMPHOCYTE;

ADENOVIRIDAE; MACACA; MUS; SUBGROUP C;

ADENOVIRUSES, HUMAN; AIDS VACCINES; ANIMALS; GENETIC VECTORS; HELPER VIRUSES; IMMUNITY; MACACA; MICE; T-LYMPHOCYTES;

EID: 63749112521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005059     Document Type: Article

References (40)

1. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, et al. (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
2. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, et al. (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305-6313.
3. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, et al. (2003) Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 7663-7668.
4. Caulfield MJ, Wang S, Smith JG, Tobery TW, Liu X, et al. (2002) Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines. J Virol 76: 10038-10043.
5. Shiver J (2003) A non-replicating adenoviral vector as a potential HIV vaccine. Res Initiat Treat Action 8: 14-16.
6. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
7. Fields PA, Kowalczyk DW, Arruda VR, Armstron E, McCleland ML, et al. (2000) Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Molecular Therapy 1: 225-235.
8. Lieber AHC, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
9. Liu Q, Muruve DA (2003) Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 10: 935-940.
10. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, et al. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46.
11. Marshall E (1999) Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.
12. Tripathy SK, Black HB, Goldwasser E, Leiden JM (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Medicine 2: 545-550.
13. Yang Y, Su Q, Wilson JM (1996) Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 70: 7209-7212.
14. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW (1998) Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. Pediatrics 101: 1013-1019.
15. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen HH, et al. (1996) In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther 3: 965-972.
16. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM (1996) Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217: 11-22.
17. Mitani K, Graham FL, Caskey CT, Kochanek S (1995) Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A 92: 3854-3858.
18. Muruve DA, Cotter MJ, Zaiss AK, White LR, Liu Q, et al. (2004) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78: 5966-5972.
19. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, et al. (1997) Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A 94: 1645-1650.
20. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, et al. (1998) High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 9: 2709-2716.
21. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, et al. (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 96: 12816-12821.
22. Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, et al. (2007) Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther 15: 732-740.
23. Mok H, Palmer DJ, Ng P, Barry MA (2005) Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79.
24. Harui A, Roth MD, Kiertscher SM, Mitani K, Basak SK (2004) Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL. Gene Ther 11: 1617-1626.
25. Parks R, Evelegh C, Graham F (1999) Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6: 1565-1573.
26. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 98: 13282-13287.
27. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, et al. (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79: 9694-9701.
28. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, et al. (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human-or chimpanzee-derived adenovirus vectors. J Virol 81: 6594-6604.
29. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, et al. (2003) Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171: 6774-6779.
30. Shashkova EV, Doronin K, Senac JS, Barry MA (2008) Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 68: 5896-5904.
31. Palmer D, Ng P (2003) Improved System for Helper-dependent adenoviral vector production. Molecular Therapy 8: 846-852.
32. Toietta G, Pastore L, Cerullo V, Finegold M, Beaudet AL, et al. (2002) Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther 5: 204-210.
33. Mercier GT, Nehete PN, Passeri MF, Nehete BN, Weaver EA, et al. (2007) Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25: 8687-8701.
34. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, et al. (2006) Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 80: 6745-6756.
35. Nehete PN, Schapiro SJ, Johnson PC, Murthy KK, Satterfield WC, et al. (1998) A synthetic peptide from the first conserved region in the envelope protein gp160 is a strong T-cell epitope in HIV-infected chimpanzees and humans. Viral Immunol 11: 147-158.
36. Nehete PN, Johnson PC, Schapiro SJ, Arlinghaus RB, Sastry KJ (1996) Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals. J Clin Immunol 16: 115-124.
37. Nehete PN, Murthy KK, Satterfield WC, Arlinghaus RB, Sastry KJ (1995) Studies on V3-specific cross-reactive T-cell responses in chimpanzees chronically infected with HIV-1IIIB. Aids 9: 567-572.
38. Sastry KJ, Arlinghaus RB (1991) Identification of T-cell epitopes without B-cell activity in the first and second conserved regions of the HIV Env protein. Aids 5: 699-707.
39. Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, et al. (2001) Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 20: 813-825.
40. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, et al. (2005) PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 12: 579-587.